Molecular endoscopy to predict response to vedolizumab therapy in ulcerative colitis (C02+)

点击翻译按钮获取中文摘要

We established molecular endoscopy as a promising novel tool to predict responsiveness to biological therapies, as it prospectively analyses the correlation between in vivo mucosal target expression and effectiveness of a biological therapy directed against it. Topical application of a GMP-conform fluorescent antibody in conjunction with endomicroscopy led to the visualization of target cells, as we conducted a clinical phase II study to predict anti-TNF responsiveness in ulcerative colitis (UC). We now apply for initiation of a trial to predict response to vedolizumab treatment in UC patients, as this would further lead to a personalized approach in individual patients.